Anemia in primary hyperparathyroidism
https://doi.org/10.35754/0234-5730-2020-65-4-514-526
Abstract
Introduction. Anaemia is a complication of primary hyperparathyroidism (PHPT). Pathogenesis of PHPT-induced anaemia involves inhibited erythroid cell proliferation associated with the underlying disease and non-specific factors (blood loss, chronic kidney disease). However, its specific mechanisms remain unclear.
Aim. Clinical description of a PHPT case with multifactorial complicating anaemia.
Main findings. With putative evidence existing on relationships between PHPT and anaemia, no large clinical trials substantiated suitable algorithms for such patients’ management. The genesis of anaemia reported in this case was multifactorial and not decisively excluding PHPT from putative causes.
About the Authors
A. M. Gorbacheva
National Research Center for Endocrinology
Russian Federation
Russian Federation
Annа M. Gorbacheva, Endocrinologist, Researcher, Department of Parathyroid Disorders
117036, Moscow
S. S. Shklyayev
National Research Center for Endocrinology; A. Tsyb Medical Radiological Research Center — Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
Stanislav S. Shklyayev, Cand. Sci. (Med.), Physician (haematology and transfusiology)
117036, Moscow
125284, Moscow
A. K. Eremkina
National Research Center for Endocrinology
Russian Federation
Russian Federation
Annа K. Eremkina, Cand. Sci. (Med.), Endocrinologist, Head of the Department of Parathyroid Disorders
117036, Moscow
A. A. Bratchikova
National Research Center for Endocrinology
Russian Federation
Russian Federation
Alina A. Bratchikova, Clinical Resident
117036, Moscow
N. G. Mokrysheva
National Research Center for Endocrinology
Russian Federation
Russian Federation
Natalya G. Mokrysheva, Dr. Sci. (Med.), Corresponding Member of Russian Academy of Sciences, Director
117036, Moscow
References
1. Yeh M.W., Ituarte P.H.G., Zhou H.C. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013; 98(3): 1122–9. DOI: 10.1210/jc.2012-4022.
2. Adami S., Marcocci C., Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 2002; 17(Suppl 2): N18–23.
3. Yu N., Donnan P.T., Murphy M.J. et al. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol. 2009; 71(4): 485–93. DOI: 10.1111/j.1365-2265.2008.03520.x.
4. Wermers R.A., Khosla S., Atkinson E.J. et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006; 21(1): 171–7. DOI: 10.1359/JBMR.050910.
5. Mokrysheva N.G., Mirnaya S.S., Dobreva E.A. et al. Primary hyperparathyroidism in Russia according to the registry. Problemy endokrinologii. 2019; 65(5): 300–10. DOI: 10.14341/probl10126 (In Russian).
6. Hunter D. Hyperparathyroidism: Generalized osteitis fibrosa with multiple osteoclastomata. Proc R Soc Med. 1931; 24(4): 486–96.
7. Aub J.C., Albright F., Bauer W. et al. Studies of calcium and phosphorus metabolism: VI. In hypoparathyroidism and chronic steatorrhea with tetany with special consideration of the therapeutic effect of thyroid. J Clin Invest. 1932; 11(1): 211–34. DOI: 10.1172/JCI100404.
8. Bernheim J., Rathaus V., Rathaus M. et al. Anemia in primary hyperparathyroidism. Nephrologie. 1986; 7(1): 28–30.
9. Mallette L.E. Hyporegenerative anemia in primary hyperparathyroidism. South Med J. 1977; 70(10): 1199–201. DOI: 10.1097/00007611-19771000000014.
10. Mallette L.E., Bilezikian J.P., Heath D.A. et al. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974; 53(2): 127–46.
11. Boxer M., Ellman L., Geller R. et al. Anemia in primary hyperparathyroidism. Arch Intern Med. 1977; 137(5): 588–93.
12. Falko J.M., Guy J.T., Smith R.E. et al. Primary hyperparathyroidism and anemia. Arch Intern Med. 1976; 136(8): 887–9.
13. Bhadada S.K., Sridhar S., Ahluwalia J. et al. Anemia and thrombocytopenia improves after curative parathyroidectomy in a patient of primary hyperparathyroidism (PHPT). J Clin Endocrinol Metab. 2012; 97(5): 1420–2. DOI: 10.1210/jc.2011-2845.
14. De Keukeleire S., Muylle K., Tsoumalis G. et al. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider? Clin Cases Miner Bone Metab. 2017; 14: 97–100. DOI: 10.11138/ccmbm/2017.14.1.097.
15. Tanaka M., Komaba H., Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial. 2018; 22(3): 242–5. DOI: 10.1111/1744-9987.12685.
16. Sonkar S.K., Singh H.P., Sonkar G.K. et al. Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease. J Fam Med Prim care. 2018; 7(4): 815–8. DOI: 10.4103/jfmpc.jfmpc_174_17.
17. Sethi S.K., Bansal S.B., Wadhwani N. et al. Myelofibrosis-induced erythropoietin-resistant anemia due to severe refractory hyperparathyroidism. Kidney Int Rep. 2018; 3: 1010–4. DOI: 10.1016/j.ekir.2018.04.003.
18. Svinareva D.A. The role of parathyroid hormone in regulation of homeostasis of bone and hemopoietic tissues. Terapevticheskiy arkhiv. 2009, 81(1): 87–91 (In Russian).
19. Kumbasar B., Taylan I., Kazancioglu R. et al. Myelofibrosis secondary to hyperparathyroidism. Exp Clin Endocrinol Diabetes. 2004; 112(3): 127–30. DOI: 10.1055/s-2004-817820.
20. Huang S.-C., Wu V.-C., Chou G. et al. Benign parathyroid adenoma presenting with unusual parathyroid crisis, anemia and myelofibrosis. J Formos Med Assoc. 2007; 106(2 Suppl): S13–6. DOI: 10.1016/s0929-6646(09)60346-6.
21. Greenfield E.M., Gornik S.A., Horowitz M.C. et al. Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993; 8(10): 1163–71. DOI: 10.1002/jbmr.5650081003.
22. Liu J.Y., Brass D.M., Hoyle G.W. et al. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol. 1998; 153(6): 1839–47. DOI: 10.1016/s0002-9440(10)65698-2.
23. Baradaran A., Nasri H. Intensification of anemia by secondary hyperparathyroidism in hemodialysis patients. Med J Islam World Acad Sci. 2001; 14(4): 161–6.
24. Bhadada S.K., Bhansali A., Ahluwalia J. et al. Anaemia and marrow fibrosis in patients with primary hyperparathyroidism before and after curative parathyroidectomy. Clin Endocrinol. 2009; 70(4): 527–32. DOI: 10.1111/j.13652265.2008.03346.x.
25. Meytes D., Bogin E., Ma A. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981; 67(5): 1263–9. DOI: 10.1172/jci110154.
26. Sikole A. Pathogenesis of anaemia in hyperparathyroidism. Med Hypotheses. 2000; 54(2): 236–8. DOI: 10.1054/mehy.1999.0027.
27. Koury M.J., Bondurant M.C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990; 248(4953): 378–81. DOI: 10.1126/science.2326648.
28. Caro J., Brown S., Miller O. et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979; 93(3): 449–58.
29. Rao D.S., Shih M.S., Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993; 328(3): 171–5. DOI: 10.1056/NEJM199301213280304.
30. Petrova N.V., Svinareva D.A., Nifontova I.N., et al. Stromal regulation of hemopoietic stem cells in long-term human bone marrow tissue cultures under the effect of parathyroid hormone. Bull Exp Biol Med. 2006;2(4):527–30. DOI: 10.1007/s10517-006-0408-5
31. Svinareva D.A., Nifontova I.N., Chertkov I.L., Drize N.I. Changed homing of hemopoietic precursor cells after long-term treatment with parathyroid hormone. Bulletin of experimental biology and medicine. 2006; 142(1): 86–9. DOI: 10.1007/s10517-006-0299-5.
32. Calvi L.M., Bromberg O., Rhee Y. et al. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012; 119(11): 2489–99. DOI: 10.1182/blood-2011-06-360933.
33. Foldes J., Wilson P., Saeed S.M. et al. Parathyroid stimulation after bleeding in man. Acta Endocrinol. 1992; 127(2): 138–41. DOI: 10.1530/acta.0.1270138.
34. Perris A.D., MacManus J.P., Whitfield J.F. et al. Parathyroid glands and mitotic stimulation in rat bone marrow after hemorrhage. Am J Physiol. 1971; 220(3): 773–8. DOI: 10.1152/ajplegacy.1971.220.3.773.
35. Panda S., Mishra A., Jena M. et al. Study of red cell fragility in different stages of chronic kidney disease in relation to parathyroid hormone. J Clin Diagn Res. 2017; 11(8): BC29–32. DOI: 10.7860/JCDR/2017/27344.10514.
36. Smith E.M., Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 2015; 22(6): 432–8. DOI: 10.1097/MED.0000000000000199.
37. Zughaier S.M., Alvarez J.A., Sloan J.H. et al. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J Clin Transl Endocrinol. 2014; 1(1): 19–25. DOI: 10.1016/j.jcte.2014.01.003.
38. Bacchetta J., Zaritsky J.J., Sea J.L. et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014; 25(3): 564–72. DOI: 10.1681/ASN.2013040355.
39. Walker M.D., Cong E., Lee J.A. et al. Vitamin D in primary hyperparathyroidism: Effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015; 100(9): 3443–51. DOI: 10.1210/jc.2015-2022.
40. Rukavitsyn O.A. Anemia of chronic diseases: the important aspects of pathogenesis and treatment. Oncohematologiya. 2016; 11(1): 37–46. DOI: 10.17650/1818-8346-2016-11-1-37-46. (In Russian).
41. Khan A.A., Hanley D.A., Rizzoli R. et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017; 28(1): 1–19. DOI: 10.1007/s00198-016-3716-2.
42. Wilhelm S.M., Wang T.S., Ruan D.T. et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 2016; 151(10): 959–68. DOI: 10.1001/jamasurg.2016.2310.
43. Hyperparathyroidism (primary): diagnosis, assessment and initial management. London, 2019. Available at: https://www.nice.org.uk/guidance/ng132/resources/hyperparathyroidism-primary-diagnosis-assessment-and-initial-management-pdf-66141715991749.
44. Herndon J.G., Helmick C.G., Sattin R.W. Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc. 1997; 45(6): 739–43. DOI: 10.1111/j.1532-5415.1997.tb01480.x.
45. Katz I.R., Beaston-Wimmer P., Parmelee P. et al. Failure to thrive in the elderly: exploration of the concept and delineation of psychiatric components. J Geriatr Psychiatry Neurol. 1993; 6(3): 161–9. DOI: 10.1177/089198879300600305.
Review
For citations:
Gorbacheva A.M., Shklyayev S.S., Eremkina A.K., Bratchikova A.A., Mokrysheva N.G. Anemia in primary hyperparathyroidism. Russian journal of hematology and transfusiology. 2020;65(4):514-526. (In Russ.) https://doi.org/10.35754/0234-5730-2020-65-4-514-526
Views:
2949
Email this article 
